LY-178210

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| image = LY-178210.svg

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class = Serotonin 5-HT_1A receptor partial agonist

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 114943-19-0

| CAS_supplemental =

| PubChem = 60845

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID = 54832

| UNII =

| KEGG =

| ChEBI =

| ChEMBL = 296753

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = LY178210; LY-228729; LY228729

| IUPAC_name = 4-(dipropylamino)-1,3,4,5-tetrahydrobenzo[cd]indole-6-carboxamide

| C=18 | H=25 | N=3 | O=1

| SMILES = CCCN(CCC)C1CC2=CNC3=C2C(=C(C=C3)C(=O)N)C1

| StdInChI = 1S/C18H25N3O/c1-3-7-21(8-4-2)13-9-12-11-20-16-6-5-14(18(19)22)15(10-13)17(12)16/h5-6,11,13,20H,3-4,7-10H2,1-2H3,(H2,19,22)

| StdInChIKey = YTOJFUORFUYGSV-UHFFFAOYSA-N

}}

LY-178210 is a selective and highly potent serotonin 5-HT_1A receptor partial agonist.{{cite journal | vauthors = Glennon RA | title=Concepts for the design of 5-HT 1A serotonin agonists and antagonists | journal=Drug Development Research | volume=26 | issue=3 | date=1992 | issn=0272-4391 | doi=10.1002/ddr.430260306 | pages=251–274 | quote=Fig. 1. Structures of some indolealkylamines: 5-HT 5-CAT (2), RU 24969 (3), (+)LSD (4), RU 28306 (5), BAY R 1531 (6), and LY 178210 (7). [...] Partial ergolines have also been examined [Flaugh et al., 1988]. For example, RU 28306 (5) binds at 5-HT1, sites with relatively low affinity (Ki = 329 nM) [Taylor et al., 1987]; however, the corresponding N,N-dipropyl-6-substituted analogs BAY R 1531 (6) [Glaser et al., 1987] and LY 178210 (7) [Slaughter et al., 1990] bind with significantly higher affinity (Ki <1 nM). These latter two agents, as with O-methyl DiPS [Glennon et al., 1988a] and N,N-dipropyl-5-carboxamidotryptamine [Hibert et al., 1987], possess 5-HT1, agonist activity. The hydroxy analog of compound 6 is apparently a full agonist [Seiler et al., 1990] whereas LY 178210 (7) acts as a partial agonist in an adenylate cyclase assay [Slaughter et al., 1990].}}{{cite book | vauthors = Audia JE, Cohen ML | title=Annual Reports in Medicinal Chemistry | chapter=Chapter 11. Serotonin Modulators and Cardiovascular/Gastrointestinal Diseases | publisher=Elsevier | volume=26 | date=1991 | isbn=978-0-12-040526-8 | doi=10.1016/s0065-7743(08)61198-7 | pages=103–112 | quote = Ergolines and Partial Ergolines - Although primarily investigated as 5-HT2 receptor ligands, several ergolines, including lisuride and lysergic acid diethylamide (LSD), show high affinity for 5-HT1A receptors, although they lack selectivity (47). Some partial ergolines, including LY 178210 (8) and LY 197206 (9), show surprising selectivity as 5-HT1A agonists relative to related ergolines (65). This specificity, however, can be more readily rationalized by recognizing the similarities to the 5-HT1A-selective aminotetralins [...] From an SAR perspective, a partial ergoline such as LY 178210 (Q) does not retain this high affinity for the 5-HT1C receptor (65). [...] Miscellaneous Structures - Many ergolines, particularly metergoline and methysergide have high affinity for the 5-HT1D receptor, while other ergolines such as mesulergine and the partial ergoline LY 178210 (9) lack significant affinity at this receptor subtype (65).}}{{cite journal | vauthors = Nelson DL | title = Structure-activity relationships at 5-HT1A receptors: binding profiles and intrinsic activity | journal = Pharmacology, Biochemistry, and Behavior | volume = 40 | issue = 4 | pages = 1041–1051 | date = December 1991 | pmid = 1816558 | doi = 10.1016/0091-3057(91)90124-k | quote = Table 3 Effect on 5-HT1A Affinity by Substitutions at the C6 Position of a Series of Tricyclic Partial Ergolines [...] }}{{cite journal | vauthors = Slaughter JL, Harrington MA, Peroutka SJ | title = 6-substituted tricyclic partial ergoline compounds are selective and potent 5-hydroxytryptamine1A receptor agents | journal = Life Sciences | volume = 47 | issue = 15 | pages = 1331–1337 | date = 1990 | pmid = 2172684 | doi = 10.1016/0024-3205(90)90197-y | doi-access = free }} It has an affinity (K_i) of 0.67{{nbsp}}nM for the serotonin 5-HT_1A receptor. The drug has high selectivity for this receptor over 12{{nbsp}}other assessed targets, including the serotonin 5-HT_1D, 5-HT_2A, 5-HT_2C, and 5-HT₃ receptors among others (K_i = ≥380–4,000{{nbsp}}nM).{{cite journal | vauthors = Perregaard J, Sánchez C, Arnt J | title=Overview: Recent Developments in Anxiolytics | journal=Current Opinion on Therapeutic Patents | volume=3 | issue=1 | date=1993 | issn=0962-2594 | doi=10.1517/13543776.3.1.101 | pages=101–128 | quote=Many of the Lilly compounds (25) were shown to have nanomolar affinity for 5-HT1D, as well as for 5-HT1A, receptors. An exception is the clinical development candidate LY 178210, which has 500-fold less affinity for 5-HT1D receptors than for 5-HT1A receptors [88].}} LY-178210 is a tricyclic simplified or partial ergoline and is structurally related to LSD.{{cite thesis | vauthors = Vangveravong S | degree = Ph.D. | title=Synthesis of trans-2-(indol-3-yl)cyclopropylamines: Rigid tryptamine analogues | date = 1994 | publisher = Purdue University | url=https://www.proquest.com/docview/304131663 | access-date=22 March 2025 | id = {{ProQuest|304131663}} | quote = Figure 5. Rigid Serotonin Receptor Ligands [...]}} It was described as a potential clinical development candidate but was not further developed and was never marketed. The drug was first reported in the scientific literature by 1990.